J&J’s Darzalex makes FDA history with another myeloma nod in new patients
Johnson & Johnson’s multiple myeloma drug Darzalex has another FDA nod in previously untreated patients under its belt—and this one is a first for a biologic. The FDA has approved Darzalex in combination with Takeda’s Velcade, thalidomide and dexamethasone (VTd) for new patients who are eligible for stem cell transplant, making it the first biologic… Read More »